METTL13 and leukemia: METTL13 knockdown significantly reduced the leukemia engraftment rate in bone marrow (29.9% in control and 14.4% in shMETTL13) and spleen (15.6% in control and 2.4% in shMETTL13) (Fig. 6F, mean values).